Bertrand Leblond

This inventor holds 23 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Allergan, Inc., Exonhit Therapeutics, Sa, Sterix Limited. Active years: 2002-2018.

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 69.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 9)

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 45(Granted Patents)

Location History:

Oxford, GB (2006)
Rouen, FR (2002 - 2011)
The Oxford Science Park, GB (2011)
Paris, FR (2011 - 2018)

Company Filing History:

Exonhit Therapeutics, Sa

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2002-2018

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9902710 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2018-02-27),

2. 9828349 - 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity (2017-11-28),

3. 9670181 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2017-06-06),

4. 9446044 - DYRK1 inhibitors and uses thereof (2016-09-20),

5. 9399628 - 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity (2016-07-26),

6. 9278943 - Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds (2016-03-08),

7. 9200016 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2015-12-01),

8. 8927589 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2015-01-06),

9. 8835463 - Compounds having analgesic and/or immunostimulant activity (2014-09-16),

10. 8772316 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) (2014-07-08),

11. 8513288 - 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity (2013-08-20),

12. 8431599 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2013-04-30),

13. 8288556 - 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity (2012-10-16),

14. 8168631 - 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity (2012-05-01),

15. 8153666 - Compounds having analgesic and/or immunostimulant activity (2012-04-10),

Title: Bertrand Leblond: A Pioneer of Innovation in Technology

Introduction

Bertrand Leblond, a visionary inventor based in Paris, FR, is renowned for his relentless pursuit of innovation and commitment to pushing the boundaries of what is possible in the world of technology. With 23 patents to his name, Leblond continues to inspire the next generation of inventors and shape the future of innovation.

Latest Patents

Leblond's latest patents showcase his expertise and groundbreaking contributions to the field of technology. One of his notable inventions includes "Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)," which have proven effective in treating central nervous system diseases such as psychosis, obesity, type II diabetes, and more. Additionally, his invention of "1-aryl-1-hydroxy-2,3-diamino-propyl amines" and related compounds with analgesic and immunostimulant properties further demonstrate his innovative prowess.

Career Highlights

Throughout his illustrious career, Leblond has made significant contributions to various companies, including Allergan, Inc. and Exonhit Therapeutics, Sa. His expertise and innovative mindset have led to the development of groundbreaking technologies that have positively impacted the field of medicine and beyond.

Collaborations

Leblond has collaborated with esteemed professionals in the industry, such as Thierry Taverne and John E Donello. Their collective efforts have resulted in the creation of cutting-edge solutions that have revolutionized the way we approach technology and healthcare.

Conclusion

Bertrand Leblond's unwavering dedication to innovation and his pioneering spirit have earned him a well-deserved reputation as a luminary in the world of technology. His remarkable inventions have not only advanced the field but have also inspired countless individuals to dream big and push the boundaries of what is possible. Leblond's legacy will continue to shape the future of innovation for years to come.